SUMMIT, NJ (
(CELG - Get Report)
reported positive results Thursday from a large phase III study seeking to establish the company's multiple myeloma drug as the preferred treatment for newly diagnosed patients.
The so-called MM-020 study achieved its primary endpoint demonstrating that treatment with a combination of Revlimid plus low-dose dexamethasone significantly delayed the time before patients' cancer returned compared to treatment with a three-drug chemotherapy regimen known as MPT, Celgene said.
Details from the MM-020 study were not released Thursday but will be presented at the American Society of Hematology annual meeting in December.
Based on results from the MM-020 study, Celgene plans to submit regulatory filings in Europe and the U.S. seeking to expand Revlimid's label to include treatment for newly diagnosed multiple myeloma patients, the company said.
Celgene shares rose 3% to $129.01 in pre-market trading.
-- Reported by Adam Feuerstein in Boston.